Announced Fri, 10 Jul · 12:24 IST
Suven to present 5 posters at AAIC 2026 on Alzheimer's drug pipeline
Compliance View source PDF
SUVEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+2.6%1-day move
₹350.00
prior close
₹346.20
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.5+0.7+0.6+0.4+2.6-0.3+2.1-2.6-7.3-2.8————
Up moveDown movePending
AI summary
Suven Life Sciences will present five scientific posters at the Alzheimer's Association International Conference (AAIC) 2026 in London from July 12-15. Key items include updates on the global Phase-3 Masupirdine trial for agitation in Alzheimer's Dementia and the Phase-2 Usmarapride program for cognitive disorders. Other posters cover SUVN-I6107, SUVN-L1101142, and SUVN-N9503012. The company will also seek strategic partnering opportunities at its Exhibit Booth 117.
Likely market impact
Pipeline visibility boost at a major global forum; may attract partnering interest but no deal or trial readout announced yet.